Abstract | BACKGROUND: METHODS: We searched MEDLINE, EMBASE, and CENTRAL for randomized controlled trials comparing coadministration of insulin glargine versus standard treatment in patients with diabetic ketoacidosis. To be eligible, studies must assess the efficacy of insulin glargine and report clinically important outcomes. Two reviewers extracted data, assessed risk of bias and summarized strength of evidence using the GRADE approach. RESULTS: Four studies (135 participants during hospital follow-up) were included in this review. Low-quality evidence from three trials suggested that subcutaneously administered insulin glargine, in addition to the standard treatment, significantly reduces the time to resolution of diabetic ketoacidosis (MD -4.19 hours; 95% CI: -7.81 to 0.57; p = 0.02). There was neutral difference between the two groups regarding length of hospital stay and hypoglycemic episodes. CONCLUSIONS:
|
Authors | Carlos Alberto Andrade-Castellanos, Luis Enrique Colunga-Lozano |
Journal | Gaceta medica de Mexico
(Gac Med Mex)
2016 Nov - Dec
Vol. 152
Issue 6
Pg. 761-769
ISSN: 0016-3813 [Print] Mexico |
Vernacular Title | Revisión sistemática con metaanálisis. Coadministración de insulina glargina en el manejo de la cetoacidosis diabética (CAD). |
PMID | 27861474
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- Hypoglycemic Agents
- Insulin Glargine
|
Topics |
- Diabetic Ketoacidosis
(drug therapy)
- Humans
- Hyperglycemia
(prevention & control)
- Hypoglycemia
- Hypoglycemic Agents
(administration & dosage)
- Injections, Subcutaneous
- Insulin Glargine
(administration & dosage)
|